Company / Capital Expenditures
Travere Therapeutics, Inc. Capital Expenditures History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$668.0K
FY2023
5-year range
$191.0K / $668.0K
FY2019-FY2023
Trend
+249.7%
vs FY2022
Sector context
#131 of 194
Health Care
What the data says
Capital Expenditures changed +250% YoY in FY2023, a notable deviation from the 7-year average annual change of +916%.
Based on SEC 10-K filings.
$668,000 in FY2023 with a 5-year CAGR of -14.1%.
Improved from $195,000 to $668,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -2.8%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Sector benchmark
#131 of 194 in Health CareTop 68% of 194This company $668.0K Sector average $117.5M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2023, capital expenditures increased 249.7% year-over-year.
- Ranks #131 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $668.0K | +249.7% |
| FY2022 | $191.0K | -2.1% |
| FY2021 | $195.0K | -73.2% |
| FY2020 | $727.0K | -18.0% |
| FY2019 | $887.0K | -37.9% |
| FY2018 | $1.4M | +6390.9% |
| FY2017 | $22.0K | -96.7% |
| FY2016 | $663.0K | +2913.6% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026